Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients

Inclusion Criteria: * Patients with non-small cell lung cancer (NSCLC) with unresectable locally advanced or metastatic disease (IIIA, IIIB or IV) of the classification tumor node, metastasis (TNM) of malignant lung tumors, 7th edition. * NSCLC patients candidates for concomitant treatment (chemotherapy plus radiotherapy or target therapy plus radiotherapy). * Evidence of measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, Karnofsky 70-100. * Life expectancy of \> 4 months at the time of screening * Patients with the ability to comply with the study and follow-up procedures. * Patients with previous surgery less than four weeks. * Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures. Exclusion Criteria: * Unstable systemic disease: active infection, heart, liver, kidney or metabolic disease; including uncontrolled chronic lung disease. * Patients treated with systemic or inhaled corticosteroids. * Patients of reproductive age without a family planning method, pregnant or lactating. * Previous diagnosis of Pneumonitis with toxicity grade ≥ 2 by CTCAE v4.0 or RTOG scale. * Patients with disease progression. * Inspiratory flow \< 90 liters / min. * Discontinue of Treatment